Skip to Main Nav Skip to Content

Zomig Logos

ZOMIG References

References:

  1. Charlesworth B, Wasiewski W, Moran D. Poster presented at: American Headache Society 44th Annual Scientific Meeting; June 21-23, 2002; Seattle, WA
  2. Dowson AJ, MacGregor EA, Purdy RA, et al. Zolmitriptan orally disintegrating tablet is effective in the acute treatment of migraine. Cephalalgia. 2002;22(2):101-106
  3. Spierings ELH, Rapoport AM, Dodick DW, Charlesworth B. Acute treatment of migraine with zolmitriptan 5 mg orally disintegrating tablet. CNS Drugs. 2004;18(15):1133-1141.
  4. ZOMIG® (zolmitriptan) Tablets and ZOMIG-ZMT® (zolmitriptan) Orally Disintegrating Tablets Prescribing Information, AstraZeneca Pharmaceuticals LP, Wilmington, DE.
  5. Visser WH, Klein KB, Cox RC, Jones D, Ferrari MD. 311C90, a new central and peripherally acting 5-HT1D receptor agonist in the acute oral treatment of migraine: a double-blind, placebo-controlled, dose-range finding study. Neurology. 1996 Feb;46(2):522-526.
  6. Rapoport AM, Ramadan NM, Adelman JU, et al. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range–finding study. Neurology. 1997;49(5):1210-1218.
  7. Dahlof C, Diener HC, Goadsby PJ, Massiou H, Olesen J, Schoenen J, Wilkinson M, Sweet RM, Klein KB. Zolmitriptan, a 5-HT1B/1D receptor agonist for the acute oral treatment of migraine: a multicentre, dose-range finding study. Eur J Neurol. 1998;5(6):535-543
  8. Geraud G, Olesen J, Pffafenrath V, et al. Comparison of the efficacy and of zolmitriptan and sumatriptan: issues migraine trial design. Cephalalgia 2000;20(1):30-8
  9. Charlesworth BR, Dowson AJ, Purdy A, Becker WJ, Boes-Hansen S, Färkkilä M Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet. CNS Drugs. 2003;17(9):653-667.
  10. Data on file, DA-ZOM-20.
  11. ZOMIG® (zolmitriptan) Nasal Spray Prescribing Information, AstraZeneca Pharmaceuticals LP, Wilmington, DE.
  12. Solomon GD, Cady RK, Klapper JA, Earl NL, Saper JR, Ramadan NM. Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. The 042 Clinical Trial Study Group. Neurology. 1997;49(5):1219-1225.
  13. Dodick D, Brandes J, Elkind A, Mathew N, Rodichok L. Speed of onset,efficacy, and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled study. CNS Drugs. 2005;19(2):125-136.
  14. Migraine Research Foundation. About migraine. http://www.migraineresearchfoundation.org/print-friendly/about-migraine.html. Accessed March 13, 2010.